Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UCB : acquires Lectus Therapeutics’ key pharmaceutical assets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/22/2011 | 08:15am CEST

Brussels (Belgium), 22 November 2011 - 07.30 AM (CET) - UCB has acquired Lectus Therapeutics's key pharmaceutical assets today via a licence and acquisition agreement. Lectus Therapeutics Ltd is a drug discovery and development company focusing on next-generation ion channel modulators. The transaction involves the acquisition of all the company's drug discovery and development programmes targeting ion channels for the treatment of a specific set of CNS indications (Central Nervous System). Financial details of the transaction were not disclosed.

Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus's proprietary LEPTICS® technology for a number of further ion channel targets.

The drug discovery and development programmes acquired by UCB centre on the use of Lectus's proprietary LEPTICS® technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.

"UCB New Medicines™ is deploying a wide range of innovative and proprietary science and technologies in its search for breakthrough medicines. Lectus's drug discovery and development programmes supports our research efforts in the CNS field. I feel confident it will enable us to further honour our commitment to deliver cutting-edge scientific research driven by the patient's needs.", says Ismail Kola, President of UCB New Medicines™.

Dr Roland Kozlowski, CEO of Lectus, commented: "We are pleased to close this transaction with UCB and anticipate that the competitive edge LEPTICS® brings, together with the enthusiasm and expertise of UCB's team, will lead to success in this challenging area of research and development. This deal executed with one of the leading global biopharmaceutical companies highlights the potential of Lectus's approach to ion channel drug discovery and the value of its LEPTICS® technology."

For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.94.14, [email protected]

France Nivelle, Global Communications, UCB
T: +32.2.559.91.78, [email protected]


Notes to the editor

About Lectus Therapeutics and LEPTICS®
Lectus Therapeutics is an emerging UK-based drug-discovery and development company, incorporated in December 2002, specialising in the discovery and development of novel drugs for pain management and associated disorders. Lectus exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels, to develop novel ion channel modulators that have the potential to offer important clinical and economic advantages over existing therapies. For further information go to . www.lectustherapeutics.com

About UCB
UCB, Brussels, Belgium ( ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). www.ucb.com

UCB Forward-Looking Statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
09/21 UCB : Studies from UCB S.A. Reveal New Findings on Extracellular Space (Quantita..
09/15 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
09/14 UCB : New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of..
09/11 UCB : EVENITYTM (romosozumab) ARCH Study Results Published in the New England &h..
09/08 UCB : highlights latest EVENITY™ (romosozumab) research at the American So..
08/28 UCB : S.A. - Transparency notification Wellington
08/24 UCB : Findings on Epilepsy Detailed by Investigators at UCB S.A. (Lacosamide and..
08/23 UCB : Transparency notification Wellington
08/17 UCB : Researchers from UCB S.A. Report on Findings in Lupus (Repeated administra..
08/03 UCB : Reports Summarize Parkinson's Disease Study Results from UCB S.A. (U18666A..
More news
News from SeekingAlpha
07/31 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
07/17 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
Financials (€)
Sales 2017 4 338 M
EBIT 2017 959 M
Net income 2017 612 M
Debt 2017 581 M
Yield 2017 2,02%
P/E ratio 2017 17,52
P/E ratio 2018 15,20
EV / Sales 2017 2,80x
EV / Sales 2018 2,58x
Capitalization 11 559 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 65,8 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-2.40%13 832
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914